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Objectives The purpose of this study was to test whether the 9p21.3 variant rs1333040 influences the occurrence of new
cardiovascular events and coronary atherosclerosis progression after early-onset myocardial infarction.
Background 9p21.3 genetic variants are associated with ischemic heart disease, but it is not known whether they influence
prognosis after an acute coronary event.
Methods Within the Italian Genetic Study of Early-onset Myocardial Infarction, we genotyped rs1333040 in 1,508 patients
hospitalized for a first myocardial infarction before the age of 45 years who underwent coronary angiography
without index event coronary revascularization. They were followed up for major cardiovascular events and an-
giographic coronary atherosclerosis progression.
Results Over 16,599 person-years, there were 683 cardiovascular events and 492 primary endpoints: 77 cardiovascular
deaths, 223 reoccurrences of myocardial infarction, and 383 coronary artery revascularizations. The rs1333040
genotype had a significant influence (p  0.01) on the primary endpoint, with an adjusted hazard ratio of 1.19
(95% confidence interval [CI]: 1.08 to 1.37) for heterozygous carriers and 1.41 (95% CI: 1.06 to 1.87) for ho-
mozygous carriers. Analysis of the individual components of the primary endpoints provided no significant evi-
dence that the rs1333040 genotype influenced the hazard of cardiovascular death (p  0.24) or the reoccur-
rence of myocardial infarction (p  0.57), but did provide significant evidence that it influenced on the hazard of
coronary revascularization, with adjusted heterozygous and homozygous ratios of 1.38 (95% CI: 1.17 to 1.63)
and 1.90 (95% CI: 1.36 to 2.65) (p  0.00015), respectively. It also significantly influenced the angiographic
endpoint of coronary atherosclerosis progression (p  0.002).
Conclusions In early-onset myocardial infarction, the 9p21.3 variant rs1333040 affects the progression of coronary athero-
sclerosis and the probability of coronary artery revascularization during long-term follow-up. (J Am Coll Cardiol
2011;58:426–34) © 2011 by the American College of Cardiology Foundation
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July 19, 2011:426–34 9p21.3 Variants and Outcomes in MIEpidemiological and family data suggest that genetic factors
have an impact on the occurrence of myocardial infarction,
particularly at an early age (1,2). Genome-wide association
studies have revealed an association between common ge-
netic variants in chromosomal region 9p21.3 and ischemic
heart disease (3–7), a finding that has been replicated in a
number of case-control studies of populations of different
ethnic origin (8–16).
See page 435
The mechanism by which 9p21.3 genetic variants influ-
ence ischemic heart disease is still unknown. Indirect data
suggest that they may affect the development and progres-
sion of coronary atherosclerosis (17–19), but no clinical
results are available currently concerning their influence on
prospectively observed cardiovascular events or the progres-
sion of coronary atherosclerosis.
The Italian Genetic Study of Early-onset Myocardial
Infarction was designed to study the genetics of suscepti-
bility to myocardial infarction. It was a prospective, nation-
wide project involving patients who were hospitalized be-
cause of a first myocardial infarction before the age of 45
years and who were followed up for the occurrence of
cardiovascular events. We assessed the influence of the
9p21.3 variant tagged by rs1333040 on the occurrence of
major adverse cardiovascular events and coronary athero-
sclerosis progression during long-term follow-up.
Methods
The Italian Genetic Study of Early-onset Myocardial In-
farction involved 125 coronary care units. It was divided into
2 parts: a case-control study and a prospective follow-up of
the cases. The cases and controls were enrolled between
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sidered eligible if they were hos-
pitalized for a first myocardial
infarction before the age of 45
years and underwent coronary
angiography without coronary revascularization for the in-
dex event; controls were eligible if they were blood donors
without a history of thromboembolic disease and were
unrelated to the patients, but were matched individually
with the patients by age, gender, and geographic origin.
Study protocol. The protocol was approved by the insti-
tutional review boards of all of the participating centers, and
all of the patients gave their written informed consent. After
identifying the patients suitable for enrollment, the investi-
gators collected their written informed consent, completed a
standardized case report form covering their family history
of cardiovascular diseases, cardiovascular risk factors, life-
styles, and medications and obtained a blood sample for
plasma separation and deoxyribonucleic acid extraction. The
patients were followed up by means of standardized tele-
phone contacts, outpatient visits, and subsequent hospital
admissions for the occurrence of endpoints. An attempt was
made to telephone all of the patients (or their families or
primary care physicians if they could not be contacted); if
they reported an event, their medical records were obtained.
Blood collection, processing, and storage. Blood was
drawn from the antecubital vein into 3 tubes containing
0.106 M trisodium citrate and was separated into plasma
and red cells by means of centrifugation. The plasma was
divided into 5 aliquots and was stored at 80°C. Deoxyri-
bonucleic acid was isolated from the white blood cells using
the salting-out method and was stored in alcohol at 20°C.
Clinical endpoints. The primary endpoint was the com-
posite of cardiovascular death, the reoccurrence of myocar-
dial infarction, and coronary artery revascularization by
means of a percutaneous coronary intervention or coronary
artery bypass surgery. Only the event that occurred first was
counted.
All deaths were investigated using the death certificate
specifying the cause of death; all other events were investi-
gated by means of source data verification. Cardiovascular
death was defined as any death attributed to a cardiovascular
cause on the death certificate. The reoccurrence of myocar-
dial infarction was defined as subsequent hospitalization
ending with a discharge diagnosis of myocardial infarction.
Rehospitalization for revascularization was defined as any
period of hospitalization during which the patient under-
went coronary revascularization percutaneously or by means
of coronary artery bypass surgery. Other thromboembolic
events were defined as any thromboembolic event requiring
hospitalization.
All of the events were adjudicated by an events committee
of 2 cardiologists who were unaware of the genotyping
results. In the case of disagreement, the opinion of a third
Abbreviations
and Acronyms
CI  confidence intervalcardiologist was required.
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absence of any narrowing in coronary diameter was consid-
ered evidence of normal coronary arteries; a narrowing of
70% (50% in the case of the left main coronary artery) was
considered nonsignificant coronary artery stenosis, and a
narrowing of 70% or more (50% or more in the case of the
left main coronary artery) was considered significant coro-
nary artery stenosis. A significant coronary artery stenosis
involving 1 of the 3 major coronary arteries was defined as
single-vessel disease; if significant coronary artery stenoses
affected 2 or 3 of the major coronary arteries, it was defined
as multivessel disease.
The extent of coronary artery disease was evaluated using
the Duke Coronary Artery Disease Index (20), which was
established in all patients on the basis of the coronary
angiography performed during hospitalization for the index
myocardial infarction. In the subset of patients who under-
went coronary angiography during follow-up, the progres-
sion of coronary artery disease was evaluated by comparing
the Duke Coronary Artery Disease Index of the first
coronary angiography with that of the follow-up coronary
angiography. If the patient underwent more than one
coronary angiography during follow-up, the last one was
used. Angiographic progression of coronary atherosclerosis
was defined as the need for angiographic assessment during
follow-up accompanied by an increase in the Duke Coro-
nary Artery Disease Index of more than the median value of
the observed changes.
Genotyping. Genotyping was performed using matrix-
assisted laser desorption ionization time-of-flight mass
spectrometry and a Sequenome MassARRAY platform
(San Diego, California). The genotyping success rate was
99.8% (range 99.6% to 99.9%); the genotyping error rate
estimated using 15 samples genotyped in quadruplicate was
0.7% (21).
Statistical analysis. This study focused on a single locus
the single nucleotide polymorphism rs1333040) and used it
as a tag for 9p21.3 genetic variants that may influence the
occurrence of cardiovascular events after early-onset myo-
cardial infarction. The locus was chosen on the basis of the
results of an earlier case-control study (also part of the
Italian Genetic Study of Early-onset Myocardial Infarction)
in which 5 9p21.3 genetic variants that have shown a
consistent signal of association with ischemic heart disease
in previous genome-wide association studies were tested for
their association with early-onset myocardial infarction.
These variants were: rs10116277, rs1333040, rs2383206,
rs10757278, and rs1333049. The single nucleotide poly-
morphism rs1333040 showed the strongest association with
early-onset myocardial infarction, with no residual associa-
tion being found at any of the remaining 4 loci, conditional
on rs1333040. These findings prompted the present inves-
tigation of the effect of rs1333040 on prospectively observed
cardiovascular events after early-onset myocardial infarction.
The primary endpoint of the analysis was the composite
of cardiovascular death, the reoccurrence of myocardial sinfarction, and coronary artery revascularization by means of
a percutaneous coronary intervention or coronary artery
bypass surgery. The primary endpoint-free time was defined
as the time between the index myocardial infarction and the
earliest of the above events, or the time of censoring.
The angiographic endpoint of progression of coronary
atherosclerosis was considered to have been met when the
increase in the Duke Coronary Artery Disease Index from
baseline to follow-up coronary angiography was more than
the median value of the observed changes. A first assessment
of the Duke Coronary Artery Disease Index was made in all
patients at the time of the baseline coronary angiography
examination, and a subsequent assessment was performed
only in those patients who repeated coronary angiography
during follow-up. The progression of coronary atheroscle-
rosis was defined as the need for an angiographic assessment
during follow-up accompanied by an increase in the Duke
Coronary Artery Disease Index of at least 19 (the median
increase in our sample) over baseline.
The dependence of primary endpoint-free time on
rs1333040 was analyzed using Cox’s regression model for
censored failure time data, adjusting for the extent of
coronary artery disease at the time of the coronary angiog-
raphy performed during the index hospitalization and the
main risk factors under a proportional hazard assumption.
Step-wise variable selection was used to isolate minimally
adequate models. This involved the interleaving of short
sequences of backward variable elimination and short se-
quences of forward inclusion. In the case of a significant
association between rs1333040 and the primary endpoint,
subsequent Cox analyses were made to test the association
with each component of the primary endpoint. The corre-
sponding estimates of heterozygous and homozygous rela-
tive risk were obtained from each of the analyses. Kaplan-
Meier estimates of the genotype-specific cumulative curves
for the various endpoints were also calculated. The depen-
dence of the number of significant coronary artery stenoses
on the number of copies of the rs1333040 risk allele was
analyzed by means of logistic regression. The association
between the 9p21.3 variant rs1333040 and coronary artery
disease, as measured at the time of the first infarction, was
tested by means of the Cochran-Armitage test of trend and
the chi-square test of association.
Results
Demographic characteristics and traditional risk factors.
The case sample consisted of 1,508 patients (1,334 men and
174 women) whose median age at the time of their first
myocardial infarction was 41 years (interquartile range: 37
to 43 years). The genotype distribution of rs1333040 in the
study population was: 141 patients had no risk allele (CC),
587 patients had 1 risk allele (CT), and 780 patients had 2
risk alleles (TT). There was no evidence of any departure
from Hardy-Weinberg equilibrium (p  0.05). Table 1
hows the demographic and angiographic characteristics of
mple si
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risk factors by genotype.
rs1333040 genotype and long-term clinical outcomes.
The patients were followed up for a median of 9.95 years
(interquartile range: 8 to 11.8 years), a total of 16,599
person-years. The vital status of 1,497 patients (99%) was
ascertained, and 1,434 (95%) completed the follow-up.
During the follow-up, there were 683 cardiovascular events
and 492 primary endpoints: 77 patients died of cardiovas-
cular death, 223 experienced reoccurrences of myocardial
infarction, and 383 underwent coronary artery revascular-
ization (230 by means of a percutaneous coronary interven-
Demographic and Angiographic Characteristics and Traditional RiskTable 1 Demographic and Angiographic Characteristics and Tra
Variable
All Patients
(n  1,508)
Patients With C/C Gen
(n  141)
Age (yrs) 41 (37–43) 35 (41–43)
Sex
Male 1,334 122 (86.52)
Female 174 19 (13.48)
Family history of CAD
Yes 1,240 115 (81.56)
No 268 26 (18.44)
Diabetes
Yes 117 12 (8.70)
No 1,384 126 (91.30)
Smoking
Yes 1,312 115 (82.14)
No 192 25 (17.86)
Hypertension
Yes 414 35 (24.82)
No 1,082 106 (75.18)
Body mass index (kg/m2)
Normal 536 62 (43.97)
Pre-obese 651 52 (36.88)
Obese 301 27 (19.15)
Hypercholesterolemia
Yes 842 78 (58.65)
No 551 55 (41.35)
Coronary artery disease
Present 1,226 101
Absent 282 36
Duke Coronary Artery Disease index 31 (23–37) 26 (19–37)
Values are median (interquartile range), n, or n (%). The frequency totals may be less than the sa
CAD  coronary artery disease.
Influence of rs1333040 Genotype on the Primarand o the Individual Components f Prima y EnTable 2 Influence of rs1333040 Genotype oand on the Individual Components o
Endpoint Genotype
Primary endpoint Heterozygous
Homozygous
Cardiovascular death Heterozygous
Homozygous
Reoccurrence of myocardial infarction Heterozygous
Homozygous
Coronary artery revascularization HeterozygousHomozygoustion and 153 by means of coronary artery bypass surgery).
During the follow-up, 53 patients experienced more than 1
myocardial infarction, 85 patients underwent more than 1
percutaneous coronary revascularization, and 2 patients
underwent more than 1 coronary artery bypass intervention.
The rs1333040 genotype had a significant (p  0.01)
influence on the primary endpoint, with an adjusted
heterozygous hazard ratio of 1.19 (95% confidence interval
[CI]: 1.08 to 1.37) and homozygous hazard ratio of 1.41
(95% CI: 1.06 to 1.87). Table 2 shows the estimated hazard
ratios, 95% CIs, and p values of the independent predictors
of the primary endpoint.
tors by rs1333040 Genotypenal Risk Factors by rs1333040 Genotype
Patients With C/T Genotype
(n  587)
Patients With T/T Genotype
(n  780) p Value
37 (41–43) 37 (40–43) 0.45
0.65
518 (88.25) 694 (88.97)
69 (11.75) 86 (11.03)
0.36
479 (81.60) 646 (82.82)
108 (18.40) 134 (17.18)
0.9
41 (7.02) 64 (8.22)
543 (92.98) 715 (91.78)
0.16
515 (88.03) 682 (87.55)
70 (11.97) 97 (12.45)
0.23
155 (26.72) 224 (28.9)
425 (73.28) 551 (71.10)
0.37
196 (33.97) 278 (36.10)
258 (44.71) 341 (44.29)
123 (21.32) 151 (19.61)
0.77
326 (60.93) 438 (60.41)
209 (39.07) 287 (39.59)
0.001
463 662
127 119
30 (23–37) 33 (23–37) 1e-06
ze of 1,508 because of missing values.
pointtPrimary Endpoint
mary Endpoint
azard Ratio 95% Confidence Interval p Value
1.19 1.08–1.37 0.01
1.41 1.06–1.87
1.10 0.80–1.40 0.24
1.20 0.60–2.50
1.05 0.86–1.28 0.47
1.10 0.74–1.64
1.38 1.17–1.63 0.00015Facditio
otypey Enddpoinn the
f Pri
H1.90 1.36–2.65
g
a
h
a
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endpoint provided no significant evidence of an influence of
the rs1333040 genotype on the hazard of cardiovascular
death (p  0.24) or the reoccurrence of myocardial infarc-
tion (p 0.47). The adjusted hazard ratio for cardiovascular
death was 1.1 (95% CI: 0.8 to 1.4) for heterozygous carriers
of the risk allele and 1.2 (95% CI: 0.6 to 2.5) for homozy-
gous carriers of the risk allele; the adjusted hazard ratio for
Figure 1 Cumulative Incidence of Cardiovascular Events After
Kaplan-Meier cumulative incidence curves of (A) the primary endpoint and the ind
(B) cardiovascular death, (C) reoccurrence of myocardial infarction, and (D) coronthe reoccurrence of myocardial infarction was 1.05 for Kheterozygous carriers of the risk allele (95% CI: 0.86 to
1.28) and 1.10 for homozygous carriers of the risk allele
(95% CI: 0.74 to 1.64), respectively. However, there was
significant evidence (p  0.00015) that the rs1333040
enotype influenced the hazard of undergoing coronary
rtery revascularization during follow-up, with an adjusted
eterozygous hazard ratio of 1.38 (95% CI: 1.17 to 1.63) and
homozygous hazard ratio of 1.90 (95% CI: 1.36 to 2.65).
Onset Myocardial Infarction by rs1333040 Genotype
components of the primary endpoint:
ery revascularization. CI  confidence interval; HR  hazard ratio.Early-
ividual
ary artaplan-Meier curves of the cumulative incidence of the pri-
ir
c
i
f
f
T
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July 19, 2011:426–34 9p21.3 Variants and Outcomes in MImary endpoint and the individual components of the primary
endpoint are shown in Figure 1 by rs1333040 genotype. Table
3 shows estimated hazard ratios, 95% CIs, and p values for the
independent predictors of the primary endpoint.
rs1333040 genotype and coronary artery disease. Coro-
nary angiography at the time of the index myocardial
infarction showed normal coronary arteries or coronary
atherosclerosis without significant stenoses in 282 patients
and significant coronary artery disease in 1,226 patients.
There was significant evidence of an association between
Figure 1 (continued)the rs1333040 genotype and the presence of significant Icoronary artery stenoses (p  0.014) and the Duke Coro-
nary Artery Disease Index (p 1 e06) at the time of the
ndex coronary angiography (Table 1).
During the follow-up, 405 patients underwent at least 1
epeat coronary angiography. The median time between the
oronary angiography performed during the index hospital-
zation and the coronary angiography performed during
ollow-up was 6.6 years (interquartile range: 4 to 9 years),
or a total of 2,625 person-years of angiographic follow-up.
he median change in the Duke Coronary Artery Diseasendex was 19 (interquartile range: 0 to 24). Individual and
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9p21.3 Variants and Outcomes in MI July 19, 2011:426–34median changes in the Duke Coronary Artery Disease
Index by rs1333040 genotype are shown in Figure 2.
The rs133340 genotype had a significant influence (p 
.002) on the angiographic endpoint of coronary atheroscle-
osis progression. The adjusted heterozygous hazard ratio
as 1.5 (95% CI: 1.17 to 2.02), and the adjusted homozy-
ous hazard ratio was 2.2 (95% CI: 1.3 to 2.7). The
aplan-Meier curves of the cumulative incidence of the
ngiographic endpoint of coronary atherosclerosis progres-
ion by rs1333040 genotype are shown in Figure 3.
iscussion
his study assessed the influence of 9p21.3 rs1333040 on
he risk of incident cardiovascular events and the progres-
ion of coronary atherosclerosis in individuals who experi-
nced a first myocardial infarction at a young age. Its major
nding is that 9p21.3 rs1333040 influences the probability
f undergoing subsequent coronary artery revascularization
fter a first myocardial infarction, even when accounting for
he extent of coronary artery disease at the time of the initial
cute coronary event. We observed that the variant was also
ssociated with the progression of coronary atherosclerosis,
hus suggesting a mechanism for the increased future
evascularization rate in carriers of the risk allele.
These results confirm the findings of genome-wide asso-
iation studies (3–7) suggesting that genetic variations in
he 9p21.3 chromosomal region represent a novel risk factor
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orphisms in strong linkage disequilibrium have been
dentified in this genomic region of approximately 50,000
ases, but they probably represent the same genetic signal
5,6). The functional effect of this signal remains unknown,
ecause there are no annotated genes in this region.
The prospective nature of our study allows a true assess-
ent of the risk of cardiovascular events after early-onset
yocardial infarction related to the 9p21.3 variation. The
s1333040 genotype significantly influenced the hazard of
he combined endpoint of cardiovascular death, myocardial
nfarction, or the need for coronary artery revascularization,
ith an estimated increased risk of 19% for heterozygous
nd 41% for homozygous carriers of the risk allele. Despite
he strong influence of the genotype on the need for
ubsequent coronary artery revascularization, no evidence
as found to support its influence on the risk of cardiovas-
ular death or the reoccurrence of myocardial infarction.
Why the 9p21.3 genetic variant rs1333040 influences the
eed for coronary artery revascularization, but does not
ffect cardiovascular death or the reoccurrence of myocardial
nfarction, remains unknown. It can be surmised that this
enetic variant influences only the development and pro-
ression of coronary atherosclerosis, and not plaque insta-
ility or coronary thrombosis. A similar observation was
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July 19, 2011:426–34 9p21.3 Variants and Outcomes in MIprevalent myocardial infarction in a population of patients
undergoing coronary angiography, although it did predict a
diagnosis of coronary artery disease.
The 9p21.3 region has been associated with the calcium
score (5,14), severe premature atherosclerosis (5), the preva-
lence of angiographic coronary artery disease (18,22), and the
progression of carotid atherosclerosis (19). In keeping with
these findings, we observed an association between the 9p21.3
genetic variant rs1333040 and the prevalence of coronary artery
disease at the time of the coronary angiography performed
during the index hospitalization. In addition, the variant
influenced the progression of coronary atherosclerosis as mea-
sured by changes in the Duke Coronary Artery Disease Index.
Carriers of 2 risk alleles showed more rapid progression of
coronary atherosclerosis, whereas carriers of 1 risk allele
showed intermediate progression between that of wild-type
and homozygous carriers, thus indicating a gene gradient for
the progression of coronary atherosclerosis.
Study limitations. One possible limitation of this study is
the use of early-onset myocardial infarction as a clinical model
to study the influence of 9p21.3 sequence variants on cardio-
vascular events and the progression of coronary atherosclerosis.
It is known that early-onset myocardial infarction is greatly
influenced by genetics (1,2), and so the effect of genetic factors
may be overestimated in this population. However, we focused
on the narrow phenotype of early-onset myocardial infarction
because its degree of inheritability makes it very promising for
fruitful genetic mapping, although future studies are clearly
Adjusted HR heterozygous vs wi
Adjusted HR homozygous vs w
p = 0.0
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Figure 3 Cumulative Incidence of the Angiographic Endpoint of
Kaplan-Meier cumulative incidence curves of the angiographic endpoint. The inset
Abbreviations as in Figure 1.needed to assess the real influence of 9p21.3 genetic variants inbroader populations of patients with all of the manifestations of
ischemic heart disease.
Another possible limitation may be related to the selection
of patients with early-onset myocardial infarction who did not
undergo coronary revascularization at the time of the index
event. We did this to be able to assess the influence of the
9p21.3 genetic variant rs1333040 on the cumulative probability
f cardiovascular events and the progression of atherosclerosis
y eliminating the interference of coronary revascularization.
owever, because it may have had an impact on the incidence
f cardiovascular events, our conclusions apply only to patients
ith early-onset myocardial infarction not undergoing coro-
ary revascularization for the index event.
Moreover, the data relating to the progression of athero-
clerosis came only from the patients who underwent repeat
oronary angiography for clinical reasons. This selection
ias may have confounding potential, but performing cor-
nary angiography for scientific reasons has ethical impli-
ations that are difficult to overcome.
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